Through our TLR immune-modulation platform, we have designed drugs that are intended to turn the immune system off or on depending on the type of condition we are treating.

Our current focus is advancing the development of TLR agonist, which are designed to turn on or activate the immune system.  Our lead TLR agonist, tilsotolimod is an agonist of TLR9 and we are delivering it intratumorally to stimulate an immune response within the tumor microenvironment to enable stronger anti-tumor activity from check point inhibitors such as anti-PD-1 inhibitors or CTLA-4 inhibitors.